Each of the four TKIs administered here are inhibitors of the VEGF receptor and are FDA approved for use in RCC.19,22–24 Furthermore, TKIs are also standard therapy in cases of EGFR overexpression. The gene discussed is EGFR; the disease is renal cell carcinoma.